Eagle Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>EP</div>
EGRX -- USA Stock  

USD 42.62  1.65  3.73%

In general, we focus on analyzing Eagle (NASDAQ:EGRX) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eagle Pharmaceuticals daily price indicators and compare them against related drivers. Let's first try to break down why Eagle Pharmaceuticals investors are seeking stability amid unprecedented economic uncertainty.
Published over a month ago
View all stories for Eagle Pharmaceuticals | View All Stories
Do you have a personal attachment to Eagle Pharmaceuticals?
The firm shows a Beta (market volatility) of 0.0453, which means not very significant fluctuations relative to the market. Let's try to break down what Eagle's beta means in this case. As returns on the market increase, Eagle Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Eagle Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Eagle Pharmaceuticals historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards predicting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Eagle Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Eagle Pharmaceuticals has an expected return of -0.0859%. Please be advised to confirm Eagle Pharmaceuticals total risk alpha, as well as the relationship between the downside variance and daily balance of power to decide if Eagle Pharmaceuticals stock performance from the past will be repeated at some point in the near future.
The successful prediction of Eagle Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Eagle Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Eagle Pharmaceuticals based on Eagle Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Eagle Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Eagle Pharmaceuticals's related companies.

Use Technical Analysis to project Eagle expected Price

Eagle Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Eagle Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Eagle Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Eagle utilizes its cash?

To perform a cash flow analysis of Eagle Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Eagle Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Eagle Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Eagle Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Eagle Pharmaceuticals reported Net Cash Flow from Operations of 49.5 Million in 2020

Exercise or conversion by Steven Ratoff of 2340 shares of Eagle Pharmaceuticals subject to Rule 16b-3

Legal trades by Eagle Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Eagle insider trading alert for exercise of stock option (right to buy) by Steven Ratoff, the corporate stakeholder, on 12th of April 2021. This event was filed by Eagle Pharmaceuticals Inc with SEC on 2021-04-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

This firm reported the previous year's revenue of 186.14 M. Net Income was 4.94 M with profit before overhead, payroll, taxes, and interest of 135 M.
 2019 2020 (projected)
Long Term Debt to Equity0.190.22
Interest Coverage42.248.52

Deferred Revenue Breakdown

Eagle Pharmaceuticals Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2021. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Eagle Pharmaceuticals Deferred Revenue is fairly stable at the moment as compared to the past year. Eagle Pharmaceuticals reported Deferred Revenue of 5.4 Million in 2020
2010
2012
2013
2014
2020
2021
20109.5 Million
201210.02 Million
20136.58 Million
20146 Million
20205.4 Million
20216.22 Million

Time to pull out from of Eagle Pharmaceuticals?

Current market risk adjusted performance is at -1.35. Eagle Pharmaceuticals exhibits very low volatility with skewness of -0.13 and kurtosis of 0.02. However, we advise investors to further study Eagle Pharmaceuticals technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eagle Pharmaceuticals' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eagle Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Eagle Pharmaceuticals

While many of the other players in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Eagle may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 2nd of March 2021, we believe that at this point, Eagle Pharmaceuticals is overvalued with very small probability of distress within the next 2 years. Our overall buy-hold-sell recommendation on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Eagle Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com